Bliss GVS Pharma Limited (BLISSGVS.BO)
INR 120.15
(3.0%)
INR 120.15
(3.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 12.13 Billion INR | 4.93% |
| 2022 | 11.56 Billion INR | 4.34% |
| 2021 | 11.08 Billion INR | 2.97% |
| 2020 | 10.76 Billion INR | 4.83% |
| 2019 | 10.27 Billion INR | 13.52% |
| 2018 | 9.04 Billion INR | 5.21% |
| 2017 | 8.6 Billion INR | -15.92% |
| 2016 | 10.22 Billion INR | 23.97% |
| 2015 | 8.25 Billion INR | 24.61% |
| 2014 | 6.62 Billion INR | 13.62% |
| 2013 | 5.82 Billion INR | 2.08% |
| 2012 | 5.7 Billion INR | 84.32% |
| 2011 | 3.09 Billion INR | 45.08% |
| 2010 | 2.13 Billion INR | 34.26% |
| 2009 | 1.59 Billion INR | 25.31% |
| 2008 | 1.26 Billion INR | 39.8% |
| 2007 | 907.67 Million INR | 57.63% |
| 2006 | 575.84 Million INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 12.82 Billion INR | 0.0% |
| 2023 Q2 | 11.97 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 12.13 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 12.13 Billion INR | 4.93% |
| 2022 Q2 | 11 Billion INR | 0.0% |
| 2022 Q4 | 11.56 Billion INR | 0.0% |
| 2022 FY | 11.56 Billion INR | 4.34% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 11.6 Billion INR | 0.0% |
| 2021 FY | 11.08 Billion INR | 2.97% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 11.08 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 10.76 Billion INR | 4.83% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 10.76 Billion INR | 0.0% |
| 2020 Q2 | 10.8 Billion INR | 0.0% |
| 2019 Q2 | 9.77 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 10.27 Billion INR | 13.52% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 10.27 Billion INR | 0.0% |
| 2018 Q2 | 8.62 Billion INR | 0.0% |
| 2018 FY | 9.04 Billion INR | 5.21% |
| 2018 Q4 | 9.04 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 FY | 8.6 Billion INR | -15.92% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 11.49 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q4 | 8.6 Billion INR | 0.0% |
| 2016 Q4 | 9.86 Billion INR | 0.0% |
| 2016 FY | 10.22 Billion INR | 23.97% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 7.91 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q4 | 8.25 Billion INR | 0.0% |
| 2015 FY | 8.25 Billion INR | 24.61% |
| 2014 FY | 6.62 Billion INR | 13.62% |
| 2013 FY | 5.82 Billion INR | 2.08% |
| 2012 FY | 5.7 Billion INR | 84.32% |
| 2012 Q2 | 8.32 Billion INR | 0.0% |
| 2012 Q4 | 5.7 Billion INR | 0.0% |
| 2011 FY | 3.09 Billion INR | 45.08% |
| 2010 FY | 2.13 Billion INR | 34.26% |
| 2009 FY | 1.59 Billion INR | 25.31% |
| 2008 FY | 1.26 Billion INR | 39.8% |
| 2007 FY | 907.67 Million INR | 57.63% |
| 2006 FY | 575.84 Million INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 81.167% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 97.307% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 57.414% |
| Granules India Limited | 55.2 Billion INR | 78.014% |
| Indoco Remedies Limited | 21.44 Billion INR | 43.402% |
| Achyut Healthcare Limited | 309.52 Million INR | -3821.752% |
| Ajanta Pharma Limited | 46.38 Billion INR | 73.83% |
| Alkem Laboratories Limited | 155.74 Billion INR | 92.206% |
| Alpa Laboratories Limited | 1.82 Billion INR | -564.69% |
| Brooks Laboratories Limited | 904.45 Million INR | -1242.101% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -12.601% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -58.649% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 96.868% |
| Eris Lifesciences Limited | 70.48 Billion INR | 82.779% |
| FDC Limited | 24.68 Billion INR | 50.817% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 91.546% |
| Gufic Biosciences Limited | 10.92 Billion INR | -11.105% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | -4.185% |
| Ipca Laboratories Limited | 111.01 Billion INR | 89.066% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -459.185% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -581.28% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -704.586% |
| Laurus Labs Limited | 83.87 Billion INR | 85.527% |
| Lupin Limited | 239.97 Billion INR | 94.942% |
| Mankind Pharma Limited | 119.63 Billion INR | 89.853% |
| Medicamen Biotech Limited | 2.94 Billion INR | -312.148% |
| Medico Remedies Limited | 961.95 Million INR | -1161.879% |
| Megasoft Limited | 3.65 Billion INR | -231.749% |
| NATCO Pharma Limited | 69.06 Billion INR | 82.424% |
| Piramal Pharma Limited | 153.11 Billion INR | 92.072% |
| RPG Life Sciences Limited | 5.12 Billion INR | -136.681% |
| Sigachi Industries Limited | 6.94 Billion INR | -74.87% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 98.58% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 46.148% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -199.97% |
| Unichem Laboratories Limited | 31.69 Billion INR | 61.7% |
| Wanbury Limited | 3.43 Billion INR | -253.389% |
| Windlas Biotech Limited | 6.26 Billion INR | -93.845% |
| ZIM Laboratories Limited | 4.46 Billion INR | -171.667% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 95.854% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -135.684% |
| Divi's Laboratories Limited | 154.7 Billion INR | 92.153% |
| Hester Biosciences Limited | 6.62 Billion INR | -83.268% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -52.811% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -230.871% |
| Bal Pharma Limited | 3.2 Billion INR | -278.873% |
| Strides Pharma Science Limited | 58.39 Billion INR | 79.214% |
| Venus Remedies Limited | 6.26 Billion INR | -93.652% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 52.989% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 44.599% |
| Shilpa Medicare Limited | 30.93 Billion INR | 60.757% |
| Aarti Drugs Limited | 24.32 Billion INR | 50.095% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 45.916% |
| Suven Life Sciences Limited | 2.84 Billion INR | -326.064% |
| Ind-Swift Limited | 6.54 Billion INR | -85.473% |
| Valiant Laboratories Limited | 3.42 Billion INR | -254.22% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 69.609% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | 48.367% |
| Themis Medicare Limited | 5.66 Billion INR | -114.307% |
| Hikal Limited | 24.87 Billion INR | 51.194% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 91.94% |
| Sequent Scientific Limited | 15.4 Billion INR | 21.197% |
| Novartis India Limited | 9.24 Billion INR | -31.239% |
| Wockhardt Limited | 76.49 Billion INR | 84.13% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 89.489% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -2478.162% |
| Neuland Laboratories Limited | 18.32 Billion INR | 33.761% |
| Morepen Laboratories Limited | 12.93 Billion INR | 6.135% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -405.649% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -264.061% |